Drugs / [18F]F-RESCA-RT4
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06715826 | Sep 2024 → Nov 2026 expected | breast carcinoma | RenJi Hospital | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06851663 | Dec 2024 → Dec 2027 expected | cervical cancer, cholangiocarcinoma, endometrial cancer, lung cancer +6 | RenJi Hospital | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07026110 | Dec 2024 → Oct 2026 expected | lung cancer | RenJi Hospital | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]F-RESCA-RT4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07026110 ↗ |